Taurolidine

DB12473

small molecule approved investigational

Deskripsi

Taurolidine is an antimicrobial used for the prevention of catheter-related infections. It is a derivative of the amino acid taurine.

It was first synthesized in the 1970s and was originally used as a prophylactic against intraperitoneal bacterial infections in patients with peritonitis.A263217 In November 2023, a catheter lock solution of taurolidine in combination with heparin - marketed as Defencath - received FDA approval under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD pathway) for the prevention of catheter-related bloodstream infections in a limited and specific patient population.L50092

Struktur Molekul 2D

Berat 284.35
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

In an aqueous solution, taurolidine exists in an equilibrium with taurultam, which is subsequently metabolized to taurinamide.A263217 Both taurultam and taurinamide contribute to the antimicrobial activity of taurolidine.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

38 Data
Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Taurolidine.
Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Taurolidine.
Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Taurolidine.
Methoxy polyethylene glycol-epoetin beta The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Taurolidine.
Lidocaine The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Lidocaine.
Ropivacaine The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Ropivacaine.
Bupivacaine The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Bupivacaine.
Cinchocaine The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Cinchocaine.
Dyclonine The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Dyclonine.
Procaine The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Procaine.
Prilocaine The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Prilocaine.
Proparacaine The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Proparacaine.
Meloxicam The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Meloxicam.
Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Oxybuprocaine.
Cocaine The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Cocaine.
Mepivacaine The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Mepivacaine.
Levobupivacaine The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Levobupivacaine.
Diphenhydramine The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Diphenhydramine.
Benzocaine The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Benzocaine.
Chloroprocaine The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Chloroprocaine.
Phenol The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Phenol.
Tetrodotoxin The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Tetrodotoxin.
Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Benzyl alcohol.
Capsaicin The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Capsaicin.
Etidocaine The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Etidocaine.
Articaine The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Articaine.
Tetracaine The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Tetracaine.
Propoxycaine The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Propoxycaine.
Pramocaine The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Pramocaine.
Butamben The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Butamben.
Butacaine The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Butacaine.
Oxetacaine The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Oxetacaine.
Ethyl chloride The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Ethyl chloride.
Butanilicaine The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Butanilicaine.
Metabutethamine The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Metabutethamine.
Quinisocaine The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Quinisocaine.
Ambroxol The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Ambroxol.
Etrasimod The risk or severity of immunosuppression can be increased when Taurolidine is combined with Etrasimod.

Referensi & Sumber

Synthesis reference: Manik Reddy Pullagurla, Jagadeesh Babu Rangisetty, Neelam Naidu Dokula, "Process for the preparation of taurolidine and its intermediates thereof" European Patent EP2643308A1, filed November 2011.
Artikel (PubMed)
  • PMID: 34767871
    van den Bosch CH, Jeremiasse B, van der Bruggen JT, Frakking FNJ, Loeffen YGT, van de Ven CP, van der Steeg AFW, Fiocco MF, van de Wetering MD, Wijnen MHWA: The efficacy of taurolidine containing lock solutions for the prevention of central-venous-catheter-related bloodstream infections: a systematic review and meta-analysis. J Hosp Infect. 2022 May;123:143-155. doi: 10.1016/j.jhin.2021.10.022. Epub 2021 Nov 9.
  • PMID: 36099103
    Wouters Y, Mennen GRH, Te Morsche RHM, Roelofs HMJ, Wanten GJA: The Antiseptic and Antineoplastic Agent Taurolidine Modulates Key Leukocyte Functions. In Vivo. 2022 Sep-Oct;36(5):2074-2082. doi: 10.21873/invivo.12933.
  • PMID: 17395893
    Gong L, Greenberg HE, Perhach JL, Waldman SA, Kraft WK: The pharmacokinetics of taurolidine metabolites in healthy volunteers. J Clin Pharmacol. 2007 Jun;47(6):697-703. doi: 10.1177/0091270007299929. Epub 2007 Mar 29.

Contoh Produk & Brand

Produk: 2 • International brands: 0
Produk
  • Defencath
    Solution • - • Intraluminal • US • Approved
  • Defencath
    Solution • - • Intraluminal • US • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul